Live
Audio Only
Rodrigo Yanez, Chile's vice trade minister who forged a deal with Sinovac to host the vaccine's clinical trial, told media that the data showed Chile had made "the right bet."
The COVID-19 vaccine developed by China's Sinovac Biotech Ltd is 80 percent effective against death from the disease, showed a recent real-world study in Chile.
RELATED:
According to the study released by the Chilean government on Friday, the Sinovac vaccine is also 67 percent effective in preventing symptomatic infection, 85 percent effective in preventing hospitalizations, and 89 percent in preventing patients from entering intensive care units.
Chinese top diplomat to #Somalia Qin Jian, embassy staff receive COVID19 jabs at a city hospital. The federal government has started inoculating its citizens using #Sinovac, a coronavirus vaccine manufactured by #Sinopharm, a Chinese owned company. �������� pic.twitter.com/8DBYxSiaL2
— Abdulaziz Billow Ali (@AbdulBillowAli) April 14, 2021
Rodrigo Yanez, Chile's vice trade minister who forged a deal with Sinovac to host the vaccine's clinical trial, told media that the data showed Chile had made "the right bet."
Speaking to Reuters, Yanez said, "It's a game-changer for that vaccine, and I think it ratifies quite graphically the discussion over its efficacy."
Newsletter
